Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.

On the primary endpoint, Praluent reduced the overall risk of MACE by 15% (HR=0.85, CI: 0.78-0.93, p=0.0003). The MACE composite endpoint includes patients who experienced a heart attack, ischemic ...

Praluent and Repatha are priced higher than Pfizer’s (PFE) Lipitor, AstraZeneca’s (AZN) Crestor, and Merck’s (MRK) Mevacor on account of better efficacy and safety profile.

In the much anticipated Odyssey trial, Praluent reduced the risk of a composite endpoint of heart attack, stroke, death from coronary heart disease or unstable angina requiring hospitalization by ...

Praluent has won the battle for UnitedHealth Group’s business in ongoing PCSK9 sweepstakes, according to an announcement this morning from Sanofi and Regeneron. UnitedHealth’s formularies will ...

Praluent and a similar drug, Amgen's Repatha, work in a different way and lower cholesterol much more. Patients give themselves shots of the medicine once or twice a month.

Bridgewater-based Sanofi and Regeneron Pharmaceuticals will make Praluent available at a new U.S. list price of $5,850 annually, a 60 percent reduction from the original price, beginning in early ...

Praluent-treated patients started the trial on 75 mg every 2 weeks, and switched to 150 mg every 2 weeks if their LDL-C levels remained above 50 mg/dL (n=2,615).

"This trial was consistent with earlier statin trials, showing the greatest benefit in patients with higher cholesterol levels at baseline," said George D. Yancopoulos, M.D., Ph.D., President and ...